Expanded Co-Pay Assistance
Program for Isentress (raltegravir)
Enhanced Program Provides Assistance to People Living with
HIV-1 Who are Privately Insured and Have Out-of-Pocket Co-Pays
Station, N.J. -- October 22, 2010 -- Merck today announced an
enhanced co-pay assistance program for people living with HIV-1
who are taking the Company's first-in-class HIV-1 integrase
inhibitor, Isentress (raltegravir) Tablets. The program provides
important savings for privately-insured patients with out-of-pocket
costs for Isentress, and is part of Merck's ongoing commitment
to providing access to treatment.
who have been prescribed Isentress who meet certain requirements
are eligible to participate in the program, in which they can
receive a Savings Coupon for up to $400 toward out-of-pocket
costs on each of up to 12 eligible prescriptions of Isentress,
regardless of the number of tablets supplied on the prescription.
The program applies to eligible patients who have private health
insurance with a co-payment for the prescription. Savings are
limited to co-pay amount and eligibility restrictions, terms
and conditions apply.
effort, along with Merck's ongoing collaboration with AIDS Drug
Assistance Programs (ADAPs), further reinforces the Company's
long-standing commitment to providing access to our medicines,"
said Patrick Bergstedt, senior vice president and general manager,
Merck Infectious Diseases Franchise. "Given today's economic
climate, programs that help alleviate the high co-pay costs
that many HIV-1 patients face are increasingly important.
program is not available to patients who are covered under Medicaid,
Medicare, a Medicare Part D or Medicare Advantage plan (regardless
of whether a specific prescription is covered), TRICARE, CHAMPUS,
Government Health Insurance Plan ("Healthcare Reform"),
or any other state or federal medical or pharmaceutical benefit
program or pharmaceutical assistance program, or to residents
of Massachusetts. Participants must be residents of the United
States or the Commonwealth of Puerto Rico to be eligible for
Eligible patients can enroll in the Savings Coupon program and
receive additional information about co-pay assistance by calling
1-877-264-2440 or at www.Isentress.com.
The Savings Coupon for Isentress expires Sept. 30, 2012.
Important information about Isentress
Isentress is indicated in combination with other antiretroviral
agents for the treatment of HIV-1 infection in adults. The label
for Isentress is based on analyses of plasma HIV-1 RNA levels
through 96 weeks in three double-blind controlled clinical studies
of Isentress. Two of these studies were conducted in clinically
advanced, three-class antiretroviral (ARV) [non-nucleoside reverse
transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase
inhibitor (NRTI), protease inhibitor (PI)] treatment-experienced
adults and one was conducted in treatment-naive adults.
The safety and efficacy of Isentress have not been established
in pediatric patients. The use of other active agents with Isentress
is associated with a greater likelihood of treatment response.
The SUPPORT Program is designed to help patients who have been
prescribed Isentress or Crixivan (indinavir sulfate). The SUPPORT
Program is a two-part program that consists of free reimbursement
support services and a patient assistance program for eligible
individuals through a single toll-free call to 1-800-850-3430.
For Information about this program and others, please visit
Isentress is the first medicine to be approved in a class
of antiretroviral drugs called integrase inhibitors. Isentress
works by inhibiting the insertion of HIV-1 DNA into human DNA
by the integrase enzyme and has demonstrated rapid antiviral
activity. Inhibiting integrase from performing this essential
function limits the ability of the virus to replicate and infect
new cells. Other HIV-1 drugs in use inhibit two other enzymes
critical to the HIV-1 replication process -- protease and reverse
transcriptase -- but Isentress is the only approved drug that
inhibits the integrase enzyme. Isentress is now approved in
more than 90 countries worldwide. Merck is continuing to move
forward with filings in additional countries around the world
for use of ISENTRESS in both treatment-experienced and treatment-naive
Merck is a global healthcare leader. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and consumer care and animal health
products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships.
For more information, visit www.merck.com.
Merck Announces Expanded Co-Pay Assistance Program for Isentress
(raltegravir). Press release. October 22, 2010.